Home/Filings/4/0001437749-21-013197
4//SEC Filing

DARGAN CHARLES K 4

Accession 0001437749-21-013197

CIK 0000880242other

Filed

May 23, 8:00 PM ET

Accepted

May 24, 8:19 PM ET

Size

19.6 KB

Accession

0001437749-21-013197

Insider Transaction Report

Form 4
Period: 2021-03-18
DARGAN CHARLES K
Chief Financial Officer
Transactions
  • Award

    Option to purchase common stock

    2021-03-18+300,0003,626,500 total
    Exercise: $0.17From: 2021-03-18Exp: 2031-03-18Common stock (300,000 underlying)
  • Award

    Option to purchase common stock

    2021-05-21+30,0003,659,000 total
    Exercise: $0.18From: 2021-05-21Exp: 2031-05-21Common stock (30,000 underlying)
  • Award

    Option to purchase common stock

    2021-05-21+2,5003,629,000 total
    Exercise: $0.18From: 2021-05-21Exp: 2031-05-21Common stock (2,500 underlying)
Footnotes (5)
  • [F1]This amount reflects, in addition to the reported option grant, the expiration, during the first quarter of 2021, of options to purchase an an aggregate 130,000 shares of common stock.
  • [F2]The Option is exercisable according to its vesting schedule: (i) 25,000 shares vested as of March 18, 2021, and then (ii) in equal monthly installments of 25,000 shares beginning April 18, 2021, so long as the Engagement Extension Agreement dated March 18, 2021, between Reporting Owner and Issuer, remains in force and effect.
  • [F3]This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from January 31, 2021, through January 31, 2022.
  • [F4]This Option was granted to Reporting Person to replace an option to purchase 10,000 shares that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and current Issuer stock price, pursuant to plan adopted by the Issuer's Compensation Committee.
  • [F5]This Option was granted to Reporting Person to replace an option to purchase 120,000 shares that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and current Issuer stock price, pursuant to plan adopted by the Issuer's Compensation Committee.

Issuer

BIOLARGO, INC.

CIK 0000880242

Entity typeother

Related Parties

1
  • filerCIK 0001112799

Filing Metadata

Form type
4
Filed
May 23, 8:00 PM ET
Accepted
May 24, 8:19 PM ET
Size
19.6 KB